| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We investigated plasma biomarker for subsidiary role on diagnosis of dementia. Plasma samples were obtained from 150 AD patients, 50 DLB patients, 14 mild cognitive impairment (MCI) patients and 279 community-dwelling healthy elderly individuals (control). We have previously identified annexin A5 and MFG-E8 as potential plasma biomarkers. The plasma level of MFG-E8 tended to be elevated in AD patients than in control. The plasma level of annexin A5 was significantly higher in both AD and DLB patients than in control. This suggests that annexin A5 is a common marker for both AD and DLB, which implies the probability of a pathological aspect of overlapping of AD and DLB. Interestingly, the level of plasma annexin A5 was also significantly higher in MCI patients than in control. This suggests that annexin A5 was elevated an early stage of the onset of AD and/or DLB and might contribute to early diagnosis of the disease.
|
